Ragu Ramanathan
Director, Global Small Molecules Bioanalysis, Pfizer, Inc., Groton, CT, USA
Project goal
Applications of Novel ADME Biomarkers and HRMS to Move New and Safer Medicines to Patients Faster
The challenges
- Using: TripleTOF® 6600, SCIEX Triple Quad™ 6500 System, X500R System
- Drug–drug interaction (DDI) potentials of new chemical entities (NCEs) are a major concern when patients require treatment with multiple drug regimens at the same time. There is a growing interest in exploring novel liquid chromatography-tandem mass spectrometry (LC-MS/MS), LC-high resolution accurate mass spectrometry (LC-HRMS), or LC-MS/HRMS assays early in drug development to ensure DDI related liabilities to establish safety and efficacy of a NCE. Without the availability of the HRMS/data independent raw data with each sample, options for post-acquisition scouting for new biomarkers, NCEs and NCE’s metabolites are limited.
Solution / Outcomes
I attend IMSC to network with the leaders in the mass spectrometry sciences and to learn and discuss about novel applications of the technology. Overall, the value for me is to bring back knowledge to develop novel and safer medicines to patients.
Why do you attend IMSC 2018? What is the value for you?
I attend IMSC to network with the leaders in the mass spectrometry sciences and to learn and discuss about novel applications of the technology. Overall, the value for me is to bring back knowledge to develop novel and safer medicines to patients.